Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 2 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q3 2026 data is still coming in (13F filing deadline: Nov 16, 2026), so these numbers are incomplete.
Q3 2026 vs. Q2 2026
How the institutions holding Nektar Therapeutics changed between Q2 2026 and Q3 2026.
All holders in Q3 2026All holders in Q2 2026
| Measure | Q2 2026 | Of which not filed for Q3 2026 | Q3 2026 | Change |
|---|---|---|---|---|
| Holders | 239 | 237 | 2 | 0 |
| Shares | 35.9M | 32.8M | 3.35M | +253.6K (+8.2%) |
| Value | $2.50B | $2.29B | $202.6M | −$13.3M (−6.2%) |
237 institutions that held it in Q2 2026 haven't filed for Q3 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Nektar Therapeutics at the end of Q3 2026 but not at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Versant Capital Management, Inc | 5 | $303 | 0.00% |
Sold out (1)
Institutions that held Nektar Therapeutics at the end of Q2 2026 and filed for Q3 2026 without it.
| Institution | Shares, Q2 2026 | Value, Q2 2026 |
|---|---|---|
| Massmutual Trust Co FSB | 106 | $7.40K |
Not filed for Q3 2026 yet (237)
Institutions that held Nektar Therapeutics at the end of Q2 2026 and haven't filed a 13F for Q3 2026. Not filing isn't selling, so they aren't counted as sold out.
Showing the largest 100 of 237 by value.